Preliminary program per March 16, 2023

_____________________________________________________________________

Day 1: Thursday August 24, 2023

09:45-10:00:    Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)

Session 1: Chairs: Bjørn Tore Gjertsen, Jeffrey Tyner

10:00-10:30:    NAMLG Keynote Lecture, Kimmo Porkka: Functional Precision Medicine for Acute Myeloid Leukemia

10:30-10:50:    Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy

10:50-11:10:    Krister Wennerberg: Repurposing through drug sensitivity screen in AML

11:10-11:30:    Caroline Heckmann: Contextual factors in drug sensitivity screen

11:30-11:50:    Päivi Östling: Harmonization of Drug sensitivity Screen

Session 2: Chair: Mika Kontro, Kim Theilgaard-Mönch

11:50-11:20:    Martin Jädersten: Real world use of venetoclax

11:20-11:50:    Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx

11:50-12:20:    Keynote Lecture, Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development

12:30-13:30:   LUNCH BREAK

Session 3: Chairs: Sören Lehmann, Oscar Brück

13:30-13:50:    Tom Erkers: Data driven hallmarks in AML

13:50-14:10:    Thoas Fioretos: Next generation genomics in diagnostics of AML

14:10-14:40:    Sören Lehmann: Chromatin structure in AML

14:50-15:30    COFFEE BREAK

Session 4: Chairs: Karl-Johan Malmberg, Oslo; Kimmo Porkka

15:30-16:00:    Keynote Lecture, Satu Mustjoki: The cellular immunological landscape of AML

16:00-16:20:    Karl-Johan Malmberg: NK immunotherapy in AML

16:20-16:50:    Arjan A van de Loosdrecht: Dendritic cell vaccine in AML CR1 MRD+

16:50-17:10:    Sébastien Walchli: CAR T in AML

18:10: RECEPTION IN HAAKONSHALLEN, BERGEN MUNCIPALITY

19:30: CONFERENCE DINNER

______________________________________________________________________

Day 2: Friday August 25, 2023

Session 5: Chairs: Anne-Sophie von Krogh, Marianne Tang Severinsen

08:15-08:45: Gunnar Juliusson: Challenges of the new AML classifications and guidelines

08:45 – 09:00: Discussion

09:00 – 09:30:  Keynote Lecture, Gerwin Huls: AML therapy backbone and the future of targeted therapies

09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring

09:50 – 10:10: Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML

10:10 – 10:40: Oscar Brück: Data Lake and collection of data for real world epidemiology

10:40 – 11:10 COFFEE BREAK

Session 6: Chairs: Caroline Heckman

11:10 – 11:40:  CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, NN

11:40 – 12:00: Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid                                                                                      malignancies

12:00 –12:30: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies

12:30 – 13:30: LUNCH BREAK

Session 7: Chairs: James Lorens, Bergen; Satu Mustjoki

13:30 – 14:00: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB, Sonia Loges: AXL in AML

14:00 – 14:15:  Bjørn Tore Gjertsen: Bemcentinib in cell fate modulation

14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB Lecture, Uwe Platzbecker: Bemcentinib and Axl in MDS and AML.

Session 8: Chair: Pia Ettala, Vladimir Lazarevic

14:45 – 15:15:  Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration

15:15 – 15:45: COFFEE BREAK

Session 9: Chairs: Jean Christoph Bourdon, Dundee; Päivi Myllynen

15:45 – 16:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB, Eva Hellström-Lindberg: TP53 mutations in MDS and AML

16:15 – 16:45: Sören Lehmann: TP53 mutations – challenges and possibilities in AML

16:45 – 17:00: Closing remarks: Mika Kontro, Secretary, NAMLG